Trial Profile
An observation of Pirfenidone in patients with rapidly progressive interstitial lung disease secondary to clinically amyopathic dermatomyositis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2016
Price :
$35
*
At a glance
- Drugs Glucocorticoids (Primary) ; Immunosuppressants (Primary) ; Pirfenidone (Primary)
- Indications Interstitial lung diseases
- Focus Therapeutic Use
- 27 Apr 2016 New trial record